Trial results for Dulce Digital-Me, an adaptive mHealth intervention for Type 2 Diabetes, were posted on 2025-06-25. The study enrolled 310 participants to compare different mobile health strategies for improving diabetes control in underserved Hispanic populations.
Background
Type 2 Diabetes is a chronic condition with significant health disparities, particularly among Hispanic populations who experience higher prevalence and poorer outcomes. Mobile health (mHealth) interventions, such as educational text messages and remote monitoring of patient-transmitted blood glucose values, are being explored as tools to improve diabetes clinical control, adherence, and patient-provider communication, especially in at-risk groups.
Trial design
This study, designated as Phase NA, enrolled 310 subjects with Diabetes Mellitus, Type 2. The trial compared Dulce Digital, an existing mHealth intervention, with Dulce Digital-Me (DD-Me), an adaptive and dynamic mHealth intervention tailored to individuals' needs and behavioral progress. The DD-Me intervention was delivered through different approaches: Automated Delivery and Medical Assistants, as well as a combined approach. While specific primary outcomes were not detailed in the posted results, key measurements included Glycosylated Hemoglobin (HbA1c) and Low-density Lipoprotein-cholesterol (LDL-C).
Key results
The study reported on Glycosylated Hemoglobin (HbA1c) and Low-density Lipoprotein-cholesterol (LDL-C) at various time points:
- Glycosylated Hemoglobin (HbA1c) 6 Months After Enrollment:
- Dulce Digital group: mean 8.17 percentage (Standard Deviation 1.51)
- Dulce Digital-Me (Automated Delivery) group: mean 7.99 percentage (Standard Deviation 1.61)
- Dulce Digital-Me (Medical Assistants) group: mean 8.44 percentage (Standard Deviation 1.48)
- Dulce Digital-Me (Combined: Automated Delivery and Medical Assistants) group: mean 8.21 percentage (Standard Deviation 1.56)
- Glycosylated Hemoglobin (HbA1c) 12 Months After Enrollment:
- Dulce Digital group: mean 8.29 percentage (Standard Deviation 1.62)
- Dulce Digital-Me (Automated Delivery) group: mean 8.41 percentage (Standard Deviation 1.70)
- Dulce Digital-Me (Medical Assistants) group: mean 8.83 percentage (Standard Deviation 1.83)
- Dulce Digital-Me (Combined: Automated Delivery and Medical Assistants) group: mean 8.62 percentage (Standard Deviation 1.77)
- Low-density Lipoprotein-cholesterol (LDL-C) 6 Months After Enrollment:
- Dulce Digital group: mean 90.27 mg/dL (Standard Deviation 33.66)
- Dulce Digital-Me (Automated Delivery) group: mean 88.20 mg/dL (Standard Deviation 36.38)
- Dulce Digital-Me (Medical Assistants) group: mean 102.93 mg/dL (Standard Deviation 47.96)
- Dulce Digital-Me (Combined: Automated Delivery and Medical Assistants) group: mean 95.69 mg/dL (Standard Deviation 43.12)
Key analyses using Logistic Regression, controlled for age, gender, employment, and language, showed p-values of 0.95, 0.37, 0.26, 0.9, 0.21, and 0.3, indicating no statistically significant differences between the intervention groups for the analyzed outcomes.
What this means
The results suggest that while mHealth interventions are a valuable tool for diabetes management, the adaptive tailoring strategies implemented in Dulce Digital-Me (Automated Delivery, Medical Assistants, or combined) did not demonstrate a statistically significant advantage over the standard Dulce Digital intervention in improving HbA1c or LDL-C levels in this population. The high p-values from the logistic regression analyses indicate that any observed differences in mean values across groups were not statistically significant, implying that these specific adaptive modifications may not have led to a distinct clinical benefit for these measured endpoints.
Source
The information for these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT03130699, titled "Dulce Digital-Me: An Adaptive mHealth Intervention for Underserved Hispanics With Diabetes", were posted on 2025-06-25 on clinicaltrials.gov.
